Summary

• British American Tobacco offers attractive risk-adjusted returns amid regulatory upheaval, with strong revenue predictability and resilient cash flow generation.
• BTI's reported GAAP revenue since 2018 averages £26 billion, with low volatility, underscoring the tobacco market's ongoing stability despite health awareness and new regulations.
• Free cash flow margins remain robust, averaging 29% (2018–2024), except for a litigation-impacted 2025, supporting solid valuation and dividend sustainability.
• My DCF analysis yields an equity value of roughly £142 billion ($190/share), materially above BTI's current ~$140 billion market cap, indicating undervaluation.

Investment Thesis

The UK parliament passed a new law that would increase the legal age for buying tobacco by 1 year each year starting January 1, 2027. This means that anyone born on or after January 1, 2009 (roughly 17 years old today) will not be able to legally purchase tobacco in the country.

This is interesting because two of the four largest tobacco companies globally are headquartered in the UK. Powerful lobbying efforts seem to have crashed on other national priorities, particularly the National Health Service "NHS" budget, which is funded by the government. According to a 2015 survey by the NHS, smoking-related hospitalizations and care cost taxpayers £2.6 billion ($3.5 billion) in England alone.

But these periods of change sometimes open the best investment opportunities. Many governments across the world, including the US and the UK, favor replacing smoking with vapes and other nicotine alternatives that are not only sold by British American Tobacco (BTI) but also differentiate it from competition, particularly Imperial Brands (IMBBY), whose efforts to advance tobacco alternatives haven't been as successful. This article won't dive into comparisons, but for perspective, smokeless nicotine products constitute 18% of BTI's sales in 2025 (p.45), while Imperial Brands was less successful in its pivot, with modern nicotine products representing about £368 million, or 1.1% of sales, in 2025 (p.41).

Note: BTI's fiscal year ends in December each year, while IMBBY's ends in September.

Revenue Resilient Despite Secular Challenges

For obvious reasons, tobacco companies benefit from customer loyalty, revenue predictability, and pricing power. A big part of the reported revenue variation is due to FX noise rather than a change in the underlying business. If anything, BTI's business is doing okay, with new nicotine products compensating for the decline in traditional tobacco smoking. For example, in 2025, BTI's adjusted revenue in constant currency

7.42K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.